160 related articles for article (PubMed ID: 38326881)
1. Time variation of high-risk groups for liver function deteriorations within fluctuating long-term liver function after hepatic radiotherapy in patients with hepatocellular carcinoma.
Tsai YL; Yu PC; Nien HH; Lu TP
Eur J Med Res; 2024 Feb; 29(1):104. PubMed ID: 38326881
[TBL] [Abstract][Full Text] [Related]
2. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
Cabibbo G; Petta S; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Negrini G; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Mega A; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Craxì A; Trevisani F; Cammà C;
J Hepatol; 2017 Jul; 67(1):65-71. PubMed ID: 28192185
[TBL] [Abstract][Full Text] [Related]
3. Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan.
Hung TH; Liang CM; Hsu CN; Tai WC; Tsai KL; Ku MK; Wang JW; Tseng KL; Yuan LT; Nguang SH; Yang SC; Wu CK; Hsu PI; Wu DC; Chuah SK
PLoS One; 2017; 12(7):e0181858. PubMed ID: 28742130
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Role of Liver Stiffness Measurements Using Magnetic Resonance Elastography in Patients with Compensated Chronic Liver Disease.
Lee DH; Lee JM; Chang W; Yoon JH; Kim YJ; Lee JH; Yu SJ; Han JK
Eur Radiol; 2018 Aug; 28(8):3513-3521. PubMed ID: 29488082
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant radiotherapy provided survival benefit compared to adjuvant radiotherapy for hepatocellular carcinoma.
Lin H; Li X; Liu Y; Hu Y
ANZ J Surg; 2018 Oct; 88(10):E718-E724. PubMed ID: 29399938
[TBL] [Abstract][Full Text] [Related]
6. Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival.
Sanford NN; Pursley J; Noe B; Yeap BY; Goyal L; Clark JW; Allen JN; Blaszkowsky LS; Ryan DP; Ferrone CR; Tanabe KK; Qadan M; Crane CH; Koay EJ; Eyler C; DeLaney TF; Zhu AX; Wo JY; Grassberger C; Hong TS
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):64-72. PubMed ID: 30684667
[TBL] [Abstract][Full Text] [Related]
7. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.
Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P
Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340
[TBL] [Abstract][Full Text] [Related]
8. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
9. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease.
Petta S; Sebastiani G; Viganò M; Ampuero J; Wai-Sun Wong V; Boursier J; Berzigotti A; Bugianesi E; Fracanzani AL; Cammà C; Enea M; Grottes MD; Di Marco V; Younes R; Keyrouz A; Mazzola S; Mendoza Y; Pennisi G; Romero-Gomez M; Craxì A; de Ledinghen V
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):806-815.e5. PubMed ID: 32621970
[TBL] [Abstract][Full Text] [Related]
10. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram.
Li X; Ye Z; Lin S; Pang H
BMC Cancer; 2021 Jun; 21(1):701. PubMed ID: 34126955
[TBL] [Abstract][Full Text] [Related]
12. The risk factors for long-term survival outcome in solitary hepatocellular carcinoma up to 2 cm: Propensity score matching analysis in a population cohort with a high rate of HBV infection.
Wang G; Zhang W; Tan Y; Jiang L; Yang J; Yang J; Yan L
Int J Surg; 2019 Dec; 72():1-6. PubMed ID: 31610283
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Hepatocellular Carcinoma Recurrence and Survival after Liver Transplantation in Patients with HCV-Related Cirrhosis.
Vidal RIO; Vidal EIO; Pereira BB; Assane CC; Ribeiro A; do Nascimento EM; Romeiro FG; Ribeiro Filho J
Biomed Res Int; 2020; 2020():1487593. PubMed ID: 33134370
[TBL] [Abstract][Full Text] [Related]
14. Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression.
D'Ambrosio R; Aghemo A; Rumi MG; Degasperi E; Sangiovanni A; Maggioni M; Fraquelli M; Perbellini R; Rosenberg W; Bedossa P; Colombo M; Lampertico P
Liver Int; 2018 Aug; 38(8):1459-1467. PubMed ID: 29377616
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular Carcinoma.
Su TS; Liang P; Liang J; Lu HZ; Jiang HY; Cheng T; Huang Y; Tang Y; Deng X
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):639-646. PubMed ID: 28581406
[TBL] [Abstract][Full Text] [Related]
16. Risk factors and surgical outcomes for spontaneous rupture of BCLC stages A and B hepatocellular carcinoma: a case-control study.
Li J; Huang L; Liu CF; Cao J; Yan JJ; Xu F; Wu MC; Yan YQ
World J Gastroenterol; 2014 Jul; 20(27):9121-7. PubMed ID: 25083085
[TBL] [Abstract][Full Text] [Related]
17. Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis.
Liu TL; Trogdon J; Weinberger M; Fried B; Barritt AS
Dig Dis Sci; 2016 Nov; 61(11):3335-3345. PubMed ID: 27480088
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (≤ 5 cm): a propensity score analysis.
Sun J; Wang Q; Hong ZX; Li WG; He WP; Zhang T; Zhang AM; Fan YZ; Sun YZ; Zheng L; Duan XZ
Hepatol Int; 2020 Sep; 14(5):788-797. PubMed ID: 32886334
[TBL] [Abstract][Full Text] [Related]
19. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
20. Adverse hepatic events caused by radiotherapy for advanced hepatocellular carcinoma.
Furuse J; Ishii H; Nagase M; Kawashima M; Ogino T; Yoshino M
J Gastroenterol Hepatol; 2005 Oct; 20(10):1512-8. PubMed ID: 16174067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
